



UNIVERSITY OF LEEDS

This is a repository copy of *Primary Prevention with Statins or Increased Physical Activity*.

White Rose Research Online URL for this paper:

<http://eprints.whiterose.ac.uk/95223/>

Version: Accepted Version

Article:

Kain, K (2016) Primary Prevention with Statins or Increased Physical Activity. *Journal of the American College of Cardiology*, 67 (16). pp. 1973-1974. ISSN 0735-1097

<https://doi.org/10.1016/j.jacc.2016.01.064>

© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International <http://creativecommons.org/licenses/by-nc-nd/4.0/>

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Letter to the Editor

Primary Prevention with Statins or Increased Physical Activity

Correspondence

Dr Kirti Kain MD FRCP FHEA

Clinical Senior Lecturer in Cardiovascular Medicine

Division of Cardiovascular & Diabetes Research

Leeds Institute of Cardiovascular and Metabolic Medicine

University of Leeds

Clarendon Way

LEEDS LS2 9JT

UK

E: k.kain@leeds.ac.uk

T: +44 (0)113 343 7745

Mortensen *et al* paper 'compares ACC/AHA Risk-Based Approach Versus Trial-Based Approaches for Primary Prevention with Statins (1). Authors acknowledge limitation that only White subjects were studied and therefore the results do not necessarily apply to other ethnicities. This will be the case especially for South Asians (originally from India, Pakistan or Bangladesh).

Statins are potent, specific, competitive inhibitors of microsomal-enzyme 3-hydroxy-3methyl-glutaryl-coenzyme-A-reductase which upregulate low-density-lipoprotein (LDL) receptors and cholesterol uptake. Statins also reduce mRNA and protein expression of GLUT2, limiting glucose uptake, inhibit L-type calcium channels that is required for insulin secretion. Statin-related muscle side effects are common and contribute significantly to rates of non-adherence. High potency statins are associated with a moderate increase in the risk of new onset diabetes.

US Food and Drug Administration has approved the first two PCSK9-inhibiting drugs to lower levels of low-density-lipoprotein-cholesterol (LDL) which is linked to cardiovascular disease. PCSK9-deficient mice have been found to be hypoinsulinemic and glucose-intolerant.

South-Asians have increased rates of ischaemic heart disease and ischaemic stroke and their adverse cardio-metabolic risk profile differs from that of the Europeans. The principle cardiovascular disease risk factor is decreased insulin sensitivity because of decreased activity/ visceral obesity resulting in abnormal glucose status along with increased triglycerides and decreased high-density-lipoprotein-cholesterol. Moreover, mean LDL concentrations are lower in South-Asians compared with Europeans (2). It is well known that South-Asians suffer from increased aches and muscle pains compared to the Europeans (3). Therefore indiscriminate use of statins in South-Asians can worsen their insulin resistance and quality of life e.g. increased aches and pains. Likewise Afro-Caribbean population do not have unfavourable lipid risk profile and have decreased ischaemic heart disease but increased insulin resistance.

Researchers reviewed 305 randomized controlled trials and concluded there were "no statistically detectable differences" between physical-activity and medications for heart disease (4). An acute bout of exercise increases skeletal muscle glucose uptake, while chronic exercise training improves mitochondrial function (5).

Human body machine has many sets of interdependent molecular clogged wheels within cell and inter cellular mechanisms. If one cog ruptures or gets dysfunctional (increased LDL cholesterol) it might be appropriate to fix it with appropriate site/function cog (drug) for secondary prevention. However, is it reasonable to insert extra cog (statin) as a primary preventative measure for generalised rusting (arteriosclerosis or atherosclerosis) when it might have detrimental effects on other cogs or their functions on the same cogwheel or other cogwheels (new-onset-diabetes and aches/pains)?

Conflict of Interest: None

References

1. Mortensen MB, Afzal S, Nordestgaard BG, Falk E. Primary Prevention With Statins: ACC/AHA Risk-Based Approach Versus Trial-Based Approaches to Guide Statin Therapy. *J Am Coll Cardiol* 2015; 66:2699-709.
2. Karthikeyan G, Teo KK, Islam S, et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study. *J Am Coll Cardiol* 2009; 53:244-53.
3. Palmer B, Macfarlane G, Afzal C, Esmail A, Silman A, Lunt M. Acculturation and the prevalence of pain amongst South Asian minority ethnic groups in the UK. *Rheumatology (Oxford)* 2007; 46:1009-14.
4. Naci H, Ioannidis JP. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. *Br J Sports Med* 2015; 49:1414-22.
5. Stanford KI, Goodyear LJ. Exercise and type 2 diabetes: molecular mechanisms regulating glucose uptake in skeletal muscle. *Adv Physiol Educ* 2014; 38:308-14.